On Thursday, Shares of Regions Financial Corporation (NYSE:RF), gained 3.35% to $9.56.
Regions Bank on Thursday declared that Kate Randall Danella has joined the company and will serve as Wealth Strategy and Effectiveness Executive for Regions Wealth Administration.
In this role, Danella will oversee the development and implementation of business strategies across Regions’ Wealth Administration Group.
Regions Wealth Administration provides banking, investment, trust and insurance services through four divisions: Regions Private Wealth Administration, Regions Institutional Services, Regions Investment Services and Regions Insurance.
Regions Financial Corporation, together with its auxiliaries, provides banking and bank-related services to individual and corporate customers in the United States. Its Corporate Bank segment offers commercial banking services, such as commercial and industrial, commercial real estate, and investor real estate lending, in addition to equipment lease financing services.
Shares of MetLife, Inc. (NYSE:MET), inclined 3.30% to $50.40, during its last trading session.
MetLife declared that it has declared a third quarter 2015 dividend of $0.25555555 per share on the company’s floating rate non-cumulative preferred stock, Series A (NYSE: METPrA). The dividend will be payable Sept. 15, 2015, to shareholders of record as of Aug. 31, 2015.
MetLife, Inc. provides life insurance, annuities, employee benefits, and asset administration products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. It operates in six segments: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; Latin America; Asia; and Europe, the Middle East and Africa.
Finally, Shire plc (NASDAQ:SHPG), ended its last trade with 4.09% gain, and closed at $232.96.
Shire declared it has reached a contract with Sanquin Blood Supply, the manufacturer of CINRYZE® (C1 esterase inhibitor [human]), providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for CINRYZE.
The specific terms of the agreement are confidential, but involve payments to Sanquin on achievement of certain milestones, counting a successful technical transfer to a second source manufacturer. Sanquin will continue to serve as a key partner with Shire to improvement global supply of CINRYZE.
Shire plc, a biopharmaceutical company, together with its auxiliaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), counting VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
